HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
about
Molecular mechanisms for enhanced DNA vaccine immunogenicity.HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance.A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.Increased humoral immunity by DNA vaccination using an α-tocopherol-based adjuvant.Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.Safety and Immunogenicity of PENNVAX®-G DNA Prime Administered by Biojector® 2000 or CELLECTRA® Electroporation Device with Modified Vaccinia Ankara-CMDR Boost.Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trialSelf-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses.Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.In silico prediction of cancer immunogens: current state of the art.Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficiency Virus Type 1 Clade C Envelope Vaccine
P2860
Q30366743-A2AB50A4-726A-471B-A707-59C173C5D184Q33869332-D10614FA-7A18-46C5-9F5E-1687B491326DQ36845154-A02377D6-6F5F-4F60-B26F-834D9A9E9B7DQ37656908-A78B820B-AE38-4F14-90D6-F912AE739826Q38659433-6D66C76D-060D-4E45-811E-10B723B9560AQ39450802-4BE2B803-08CD-47FD-9DCA-0D80E9EFE636Q40160424-267FB3D2-968A-403E-9D0C-6F090C832D6DQ40393896-BD223132-6F25-4BDB-AC4A-E1473438CB6BQ41926555-87EEA54F-FFFC-4D4A-84A7-921C82E3B18DQ42376121-EE4385D0-F82E-4C3B-9827-F1C9A2672CB9Q47257240-095E166D-13DB-4263-93AB-7F5A543002F0Q55154648-BE03DEDD-50C0-448E-A351-12D07C1979B4Q55385621-154DD8BA-36C7-4E1A-B017-DA7AC0C41533Q58727008-6AD4FA59-22DF-4346-B84A-D3EC9F5CCBA7
P2860
HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
HIV-DNA Given with or without ...... s: A Phase I Randomized Trial.
@ast
HIV-DNA Given with or without ...... s: A Phase I Randomized Trial.
@en
type
label
HIV-DNA Given with or without ...... s: A Phase I Randomized Trial.
@ast
HIV-DNA Given with or without ...... s: A Phase I Randomized Trial.
@en
prefLabel
HIV-DNA Given with or without ...... s: A Phase I Randomized Trial.
@ast
HIV-DNA Given with or without ...... s: A Phase I Randomized Trial.
@en
P2093
P2860
P50
P921
P1433
P1476
HIV-DNA Given with or without ...... s: A Phase I Randomized Trial.
@en
P2093
Andreas Bråve
Bo Hejdeman
Charlotta Nilsson
Eric Sandström
Karina Godoy-Ramirez
Patricia L Earl
Richard R Stout
Teghesti Tecleab
P2860
P304
P356
10.1371/JOURNAL.PONE.0131748
P407
P577
2015-06-29T00:00:00Z